Clinical Trial Update: Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ivosidenib in patients with conventional chondrosarcoma carrying an IDH1 mutation; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondrosarcoma

Drugs mentioned

• Ivosidenib (ivosidenib)

Snippet

Sponsor: Servier Bio-Innovation LLC | Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | Status: RECRUITING